Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies.
Vogt AS, Jörg L, Martina B, Krenger PS, Chang X, Zeltins A, Vogel M, Mohsen MO, Bachmann MF. Vogt AS, et al. Among authors: krenger ps. Front Immunol. 2022 Jun 16;13:864718. doi: 10.3389/fimmu.2022.864718. eCollection 2022. Front Immunol. 2022. PMID: 35784292 Free PMC article.
A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2.
Mohsen MO, Balke I, Zinkhan S, Zeltina V, Liu X, Chang X, Krenger PS, Plattner K, Gharailoo Z, Vogt AS, Augusto G, Zwicker M, Roongta S, Rothen DA, Josi R, Costa JJD, Sobczak JM, Nonic A, Brand LA, Nuss K, Martina B, Speiser DE, Kündig T, Jennings GT, Walton SM, Vogel M, Zeltins A, Bachmann MF. Mohsen MO, et al. Among authors: krenger ps. Allergy. 2022 Jan;77(1):243-257. doi: 10.1111/all.15080. Epub 2021 Sep 20. Allergy. 2022. PMID: 34496033 Free PMC article.
Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern.
Rothen DA, Krenger PS, Nonic A, Balke I, Vogt AS, Chang X, Manenti A, Vedovi F, Resevica G, Walton SM, Zeltins A, Montomoli E, Vogel M, Bachmann MF, Mohsen MO. Rothen DA, et al. Among authors: krenger ps. Allergy. 2022 Aug;77(8):2446-2458. doi: 10.1111/all.15311. Epub 2022 Apr 15. Allergy. 2022. PMID: 35403221 Free PMC article.
The next generation virus-like particle platform for the treatment of peanut allergy.
Sobczak JM, Krenger PS, Storni F, Mohsen MO, Balke I, Reseviča G, Heath MD, Carreno Velazquez TL, Kramer MF, Scott CJW, Skinner MA, Zeltiņš A, Kündig TM, Vogel M, Bachmann MF. Sobczak JM, et al. Among authors: krenger ps. Allergy. 2023 Jul;78(7):1980-1996. doi: 10.1111/all.15704. Epub 2023 Mar 29. Allergy. 2023. PMID: 36883475 Free article.
BALB/c and C3H mice are both suitable as peanut allergy models.
Krenger PS, Sobczak J, Paolucci M, Kündig TM, Johansen P, Vogel M, Bachmann MF. Krenger PS, et al. Clin Exp Allergy. 2023 Dec;53(12):1310-1313. doi: 10.1111/cea.14398. Epub 2023 Oct 4. Clin Exp Allergy. 2023. PMID: 37792733 Free article. No abstract available.
Correction: Rothen et al. Preclinical Evaluation of Novel Sterically Optimized VLP-Based Vaccines against All Four DENV Serotypes. Vaccines 2024, 12, 874.
Rothen DA, Dutta SK, Krenger PS, Vogt AS, Lieknina I, Sobczak JM, Osterhaus ADME, Mohsen MO, Vogel M, Martina B, Tars K, Bachmann MF. Rothen DA, et al. Among authors: krenger ps. Vaccines (Basel). 2024 Oct 18;12(10):1189. doi: 10.3390/vaccines12101189. Vaccines (Basel). 2024. PMID: 39460367 Free PMC article.
13 results